Umbilical cord mesenchymal stem cell transplantation for liver cirrhosis: a repeated measurement analysis

doi:10.3969/j.issn.2095-4344.2015.19.013

Abstract

Abstract:

BACKGROUND: The research for mesenchymal stem cells in the treatment of liver cirrhosis has made great progress. However, t-test analysis is often misused in clinical practice.
OBJECTIVE: To analyze the efficacy and safety of umbilical cord mesenchymal stem cell therapy for liver cirrhosis by repeated measurement method.
METHODS: A total of 27 patients with decompensated liver cirrhosis underwent conventional medical treatments, including liver protection treatment and symptomatic treatment. At 1 week after hospitalization, patients were given intravenous transplantation of umbilical cord mesenchymal stem cells (passages 2-4), cell viability ≥ 90%, stem cell counting ≥ 2×107 cells, four times with an interval of 5-7 days. Analysis of variance based on repeated measurement data was performed to analyze the liver function changes at different time after umbilical cord mesenchymal stem cell transplantation.
RESULTS AND CONCLUSION: The results of univariate repeated measurement showed that at 2 and 3 months after treatment, the serum albumin level was increased and the total bilirubin level in serum was decreased significantly (P < 0.05); at 3 months after treatment, the content of aspartate aminotransferase decreased, and the content of cholinesterase increased significantly (P < 0.05). No patient appeared to have liver and other organ tumors during the observation period. These findings indicate that umbilical cord mesenchymal stem cell transplantation is effective and safe in the treatment of liver cirrhosis, which can significantly improve patient’s liver functions.

CLC Number:

R394.2

Chen Jian-hua, Hu Xiang. Umbilical cord mesenchymal stem cell transplantation for liver cirrhosis: a repeated measurement analysis [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(19): 3027-3031.

Figures/Tables 2

References

[1] 陈建华,徐玉琴,张军. 间充质干细胞移植治疗终末期肝病前后血清甲胎球蛋白的变化[J]. 分子诊断与治疗杂志,2015, 7(2): 111-113.
[2] Ma XR, Tang YL, Xuan M, et al. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol Res Pract. 2015;2015:908275.
[3] 董燕慧,脐带血干细胞及脐带间充质干细胞对失代偿期肝炎后肝硬化患者肝脏功能恢复的研究[D]. 张家口:河北北方学院, 2013.
[4] 陈建华,张军,胡祥. 干细胞在非肿瘤性疾病中的注册临床研究[J]. 分子诊断与治疗杂志,2012, 4(6):400-407.
[5] Lee AY, Lee J, Kim CL, et al. Comparative studies on proliferation, molecular markers and differentiation potential of mesenchymal stem cells from various tissues (adipose, bone marrow, ear skin, abdominal skin, and lung) and maintenance of multipotency during serial passages in miniature pig. Res Vet Sci. 2015 Mar 16. [Epub ahead of print]
[6] Dueñas F, Becerra V, Cortes Y, et al. Hepatogenic and neurogenic differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses. BMC Vet Res. 2014;10:154.
[7] Swartzlander MD, Blakney AK, Amer LD,et al. Immunomodulation by mesenchymal stem cells combats the foreign body response to cell-laden synthetic hydrogels. Biomaterials. 2015;41:79-88.
[8] Jung KH, Shin HP, Lee S, et al. Effect of human umbilical cord blood-derived mesenchymal stem cells in a cirrhotic rat model. Liver Int. 2009;29(6):898-909.
[9] Bornstein R, Macias MI, de la Torre P, et al. Human decidua-derived mesenchymal stromal cells differentiate into hepatic-like cells and form functional three-dimensional structures. Cytotherapy. 2012;14(10):1182-1192.
[10] Banas A, Teratani T, Yamamoto Y, et al. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells. 2008;26(10):2705-2712.
[11] 张晓冬,宗英,陆国才,等. 药物长期毒性试验血液和生化指标的统计处理[J]. 中国新药杂志,2010,19(4):270-272,289.
[12] 邱宏,金国琴,金如锋,等. 水迷宫重复测量数据的方差分析及其在SPSS中的实现[J].中西医结合学报,2007,5(1):101-105.
[13] 师丽娜,脐血干细胞移植治疗失代偿期肝硬化临床有效性观察以及疗效指标意义观察[D]. 济南:山东大学, 2013.
[14] 温泽淮.中药临床试验重复测量设计与分析方法的探讨[D].广州: 广州中医药大学,2006.
[15] 陈平雁. 定量数据重复测量的方差分析[J]. 中华创伤骨科杂志, 2003,5(1):67-70.
[16] Ramachandran J, Sajith KG, Priya S,et al. Serum cholinesterase is an excellent biomarker of liver cirrhosis. Trop Gastroenterol. 2014;35(1):15-20.
[17] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.
[18] Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27 Suppl 2:112-120.
[19] 刘璐,廉恒丽. 熊去氧胆酸胶囊治疗肝硬化黄疸80例疗效分析[J].中国现代医药杂志,2015,17(2):64-65.
[20] 李浩,人脐血干细胞移植治疗失代偿期肝硬化的临床研究[D]. 合肥:安徽医科大学, 2014.
[21] 王方,云升皓,周新人,等. 经肝动脉自体骨髓或脐带血干细胞移植治疗失代偿期肝硬化患者的安全性和近期疗效比较[J]. 实用肝脏病杂志,2014,17(4):356-359.
[22] Yu J, Cao H, Yang J, et al. In vivo hepatic differentiation of mesenchymal stem cells from human umbilical cord blood after transplantation into mice with liver injury. Biochem Biophys Res Commun. 2012;422(4):539-545.
[23] Meier RP, Mahou R, Morel P, et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. J Hepatol. 2015;62(3):634-641.
[24] Ahmed SK, Mohammed SA, Khalaf G, et al. Role of Bone Marrow Mesenchymal Stem Cells in the Treatment of CCL4 Induced Liver Fibrosis in Albino Rats: A Histological and Immunohistochemical Study. Int J Stem Cells. 2014;7(2): 87-97.
[25] Yu J, Su X, Zhu C, et al. GFP Labeling and Hepatic Differentiation Potential of Human Placenta-Derived Mesenchymal Stem Cells. Cell Physiol Biochem. 2015; 35(6):2299-2308.
[26] Pan XN, Zheng LQ, Lai XH. Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis. World J Gastroenterol. 2014; 20(38):14051-14057.
[27] Berardis S, Dwisthi Sattwika P, Najimi M,et al. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroenterol. 2015; 21(3):742-758.
[28] Salama H, Zekri AR, Medhat E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014;5(3):70.
[29] Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015;19(3):511-520.
[30] Zhao W, Li JJ, Cao DY, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol. 2012;18(10):1048-1058.